Drug resistant TB: UK multicentre study (DRUMS): Treatment, management and outcomes in London and West Midlands 2008–2014

Journal of Infection

Volumn 74, Issue 3, 2017, Pages 260-271

  Arnold, Amber ^a,b   Cooke, Graham S ^c   Kon, Onn Min ^e   Dedicoat, Martin ^d   Lipman, Marc ^f   Loyse, Angela ^a   Butcher, Philip D ^a   Ster, Irina Chis ^a   Harrison, Thomas Stephen ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^e IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Tuberculosis

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BEDAQUILINE; CAPREOMYCIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; DRUG MEGADOSE; ENGLAND; FEMALE; HOSPITAL ADMISSION; HUMAN; LENGTH OF STAY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; PATIENT COMPLIANCE; PROGNOSIS; SPUTUM CULTURE; THORAX RADIOGRAPHY; TREATMENT OUTCOME; UNITED KINGDOM; ANTIBIOTIC RESISTANCE; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE MANAGEMENT; DRUG EFFECTS; GENETICS; ISOLATION AND PURIFICATION; MEDICATION COMPLIANCE; MICROBIOLOGY; MULTICENTER STUDY; MYCOBACTERIUM TUBERCULOSIS; RETROSPECTIVE STUDY; SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

ADULT; ANTITUBERCULAR AGENTS; CLINICAL PROTOCOLS; DISEASE MANAGEMENT; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; LENGTH OF STAY; LONDON; MALE; MEDICATION ADHERENCE; MYCOBACTERIUM TUBERCULOSIS; RETROSPECTIVE STUDIES; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; UNITED KINGDOM; YOUNG ADULT;

EID: 85008675619     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2016.12.005     Document Type: Article

References (37)

1. 1 Wu, S., Zhang, Y., Sun, F., Chen, M., Zhou, L., Wang, N., et al. Adverse events associated with the treatment of multidrug-resistant tuberculosis: a systematic review and meta-analysis. Am J Ther 23:2 (2013), e521–e530, 10.1097/01.mjt.0000433951.09030.5a.
2. 2 Tuberculosis in England: 2015 report version 1.1, 2015, Public Health England, London.
3. 3 White, V.L., Moore-Gillon, J., Resource implications of patients with multidrug resistant tuberculosis. Thorax 55:11 (2000), 962–963.
4. 4 Guidelines for the programmatic management of drug-resistant tuberculosis, 2008, World Health Organization, Geneva, Switzerland.
5. 5 Guidelines for the programmatic management of drug-resistant tuberculosis-2011 update, 2011, World Health Organisation, Geneva, Switzerland.
6. 6 Lange, C., Abubakar, I., Alffenaar, J.-W.C., Bothamley, G., Caminero, J.A., Carvalho, A.C.C., et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Resp J 44:1 (2014), 23–63.
7. 7 Sturdy, A., Goodman, A., Jose, R.J., Loyse, A., O'Donoghue, M., Kon, O.M., et al. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. J Antimicrob Chemother 66:8 (2011), 1815–1820.
8. 8 Esposito, S., Bianchini, S., Blasi, F., Bedaquiline and delamanid in tuberculosis. Expert Opin Pharmacother 16:15 (2015), 2319–2330.
9. 9 Drobniewski, F., Cooke, M., Jordan, J., Casali, N., Mugwagwa, T., Broda, A., et al. Systematic review, meta-analysis and economic modelling of molecular diagnostic tests for antibiotic resistance in tuberculosis. Health Technol Assess 19:34 (2015), 1–188 vii–viii.
10. 10 Wolfson, L.J., Walker, A., Hettle, R., Lu, X., Kambili, C., Murungi, A., et al. Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK. PLoS One, 10(3), 2015, e0120763.
11. 11 Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control, CG117.2011, National Institute for Health and Care Excellence (NICE): London.
12. 12 Tuberculosis; NICE Guideline (NG 33), 2016, National Institute for Clinical Excellence (NICE), London.
13. 13 Definitions and reporting framework for tuberculosis – 2013 revision (updated December 2014), 2014, World Health Organisation, Geneva, Switzerland.
14. 14 Anderson, L., Tamne, S., Watson, J., Cohen, T., Mitnick, C., Brown, T., et al. Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: retrospective-prospective cohort study from 2004 to 2007. Euro Surveill 18:40 (2013), 1028–1035.
15. 15 Policy statement: automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MT, 2011, World Health Organisation (WHO).
16. 16 Chang, K., Lu, W., Wang, J., Zhang, K., Jia, S., Li, F., et al. Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a meta-analysis. J Infect 64:6 (2012), 580–588.
17. 17 England, L., The Health Protection (Part 2A Orders) Regulations 2010 No. 658. 2010.
18. 18 Cooke, G.S., Beaton, R.K., Lessells, R.J., John, L., Ashworth, S., Kon, O.M., et al. International spread of MDR TB from Tugela Ferry, South Africa. Emerg Infect Dis 17:11 (2011), 2035–2037.
19. 19 Tuberculosis surveillance and monitoring in Europe 2014, 2014, European Centre for Disease Prevention and Control, Stockholm.
20. 20 Karo, B., Hauer, B., Hollo, V., van der Werf, M.J., Fiebig, L., Haas, W., Tuberculosis treatment outcome in the European Union and European Economic Area: an analysis of surveillance data from 2002–2011. Euro Surveill, 20(49), 2015.
21. 21 Ahuja, S.D., Ashkin, D., Avendano, M., Banerjee, R., Bauer, M., Bayona, J.N., et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med, 9(8), 2012, 1212.
22. 22 Marks, S.M., Flood, J., Seaworth, B., Hirsch-Moverman, Y., Armstrong, L., Mase, S., et al. Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005–2007. Emerg Infect Dis 20:5 (2014), 812–821.
23. 23 van Altena, R., de Vries, G., Haar, C., de Lange, W., Magis-Escurra, C., van den Hof, S., et al. Highly successful treatment outcome of multidrug-resistant tuberculosis in the Netherlands, 2000–2009. Int J Tuberc Lung Dis 19:4 (2015), 406–412.
24. 24 Brode, S.K., R.V., McNamee, J., Malek, N., Stewart, S., Multidrug-resistant tuberculosis: treatment and outcomes of 93 patients/La tuberculose multirésistante: le traitement et ses résultats chez 93 patients. Can Respir J, 22(2), 2015, 97.
25. 25 Abubakar, I., Moore, J., Drobniewski, F., Kruijshaar, M., Brown, T., Yates, M., et al. Extensively drug-resistant tuberculosis in the UK: 1995 to 2007. Thorax 64:6 (2009), 512–515.
26. 26 Falzon, D., Gandhi, N., Migliori, G.B., Sotgiu, G., Cox, H., Holtz, T.H., et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on MDR-TB outcomes. Eur Respir J 42:1 (2012), 156–168.
27. 27 Stopping tuberculosis in England: an action plan from the Chief Medical Officer, 2004, Department of Health (DOH), London.
28. 28 Sotgiu, G., Pontali, E., Centis, R., D'Ambrosio, L., Migliori, G.B., Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis. Expert Rev Anti Infect Ther 13:3 (2015), 305–315.
29. 29 Wolfson, L.J., Gibbert, J., Wirth, D., Diel, R., Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany. Eur Respir J 46:6 (2015), 1826–1829.
30. 30 Sinanovic, E., Ramma, L., Vassall, A., Azevedo, V., Wilkinson, L., Ndjeka, N., et al. Impact of reduced hospitalisation on the cost of treatment for drug-resistant tuberculosis in South Africa. Int J Tuberc Lung Dis 19:2 (2015), 172–178.
31. 31 Cox, H., Ramma, L., Wilkinson, L., Azevedo, V., Sinanovic, E., Cost per patient of treatment for rifampicin-resistant tuberculosis in a community-based programme in Khayelitsha, South Africa. Trop Med Int Health 20:10 (2015), 1337–1345.
32. 32 Nunn, A.J., Rusen, I., Van Deun, A., Torrea, G., Phillips, P.P., Chiang, C.-Y., et al. Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials, 15(1), 2014, 353.
33. 33 The WHO treatment guidelines for drug-resistant tuberculosis (2016 update), 2016, World Health Organisation, Geneva.
34. 34 Baral, S.C., Aryal, Y., Bhattrai, R., King, R., Newell, J.N., The importance of providing counselling and financial support to patients receiving treatment for multi-drug resistant TB: mixed method qualitative and pilot intervention studies. BMC Public Health, 14, 2014, 46.
35. 35 The Interdepartmental Working Group on Tuberculosis: The prevention and control of tuberculosis in the United Kingdon, 1998, Department of Health (DOH), London.
36. 36 Epstein, M.D., Schluger, N.W., Davidow, A.L., Bonk, S., Rom, W.N., Hanna, B., Time to detection of Mycobacterium tuberculosis in sputum culture correlates with outcome in patients receiving treatment for pulmonary tuberculosis. Chest 113:2 (1998), 379–386.
37. 37 Dharmadhikari, A.S., Mphahlele, M., Venter, K., Stoltz, A., Mathebula, R., Masotla, T., et al. Rapid impact of effective treatment on transmission of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 18:9 (2014), 1019–1025.